[HTML][HTML] Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults
MJM Bonten, SM Huijts, M Bolkenbaas… - … England Journal of …, 2015 - Mass Medical Soc
Background Pneumococcal polysaccharide conjugate vaccines prevent pneumococcal
disease in infants, but their efficacy against pneumococcal community-acquired pneumonia in …
disease in infants, but their efficacy against pneumococcal community-acquired pneumonia in …
Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021
Importance Some individuals experience persistent symptoms after initial symptomatic
SARS-CoV-2 infection (often referred to as Long COVID). Objective To estimate the proportion of …
SARS-CoV-2 infection (often referred to as Long COVID). Objective To estimate the proportion of …
[HTML][HTML] A global systematic analysis of the occurrence, severity, and recovery pattern of long COVID in 2020 and 2021
Objective: To estimate by country and territory of the number of patients affected by long
COVID in 2020 and 2021, the severity of their symptoms and expected pattern of recovery …
COVID in 2020 and 2021, the severity of their symptoms and expected pattern of recovery …
Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands
…, MH Rozenbaum, SM Huijts… - European …, 2015 - Eur Respiratory Soc
The Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) demonstrated
the efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) in preventing vaccine-…
the efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) in preventing vaccine-…
[HTML][HTML] Incidence, direct costs and duration of hospitalization of patients hospitalized with community acquired pneumonia: a nationwide retrospective claims …
MH Rozenbaum, MJJ Mangen, SM Huijts… - Vaccine, 2015 - Elsevier
Background Community-acquired pneumonia (CAP) is one of the most common acute
infections associated with a substantial clinical and economic burden. There have been few …
infections associated with a substantial clinical and economic burden. There have been few …
Validation of an immunodiagnostic assay for detection of 13 Streptococcus pneumoniae serotype-specific polysaccharides in human urine
MW Pride, SM Huijts, K Wu, V Souza… - Clinical and vaccine …, 2012 - Am Soc Microbiol
To improve the clinical diagnosis of pneumococcal infection in bacteremic and nonbacteremic
community-acquired pneumonia (CAP), a Luminex technology-based multiplex urinary …
community-acquired pneumonia (CAP), a Luminex technology-based multiplex urinary …
[HTML][HTML] The impact of community-acquired pneumonia on the health-related quality-of-life in elderly
MJJ Mangen, SM Huijts, MJM Bonten… - BMC infectious diseases, 2017 - Springer
Background The sustained health-related quality-of-life of patients surviving community-acquired
pneumonia has not been accurately quantified. The aim of the current study was to …
pneumonia has not been accurately quantified. The aim of the current study was to …
The impact of age on the efficacy of 13-valent pneumococcal conjugate vaccine in elderly
…, SM Huijts, M Bolkenbaas… - Clinical Infectious …, 2015 - academic.oup.com
In a post hoc analysis of the Community-Acquired Pneumonia (CAP) immunization Trial in
Adults the model-predicted 13-valent pneumococcal conjugate vaccine efficacy for preventing …
Adults the model-predicted 13-valent pneumococcal conjugate vaccine efficacy for preventing …
[HTML][HTML] Post-hoc analysis of a randomized controlled trial: Diabetes mellitus modifies the efficacy of the 13-valent pneumococcal conjugate vaccine in elderly
SM Huijts, CH van Werkhoven, M Bolkenbaas… - Vaccine, 2017 - Elsevier
… The research funding of SM Huijts, M. Bolkenbaas and CH van Werkhoven was partially
supported by grants provided to UMCU (University Medical Center Utrecht) by Pfizer. SM Huijts …
supported by grants provided to UMCU (University Medical Center Utrecht) by Pfizer. SM Huijts …
[HTML][HTML] Physical recovery across care pathways up to 12 months after hospitalization for COVID-19: A multicenter prospective cohort study (CO-FLOW)
…, MH Heijenbrok-Kal, LM Bek, SM Huijts… - The Lancet Regional …, 2022 - thelancet.com
Backgroud The sudden COVID-19 pandemic forced quick development of care pathways
for patients with different needs. Trajectories of physical recovery in hospitalized patients for …
for patients with different needs. Trajectories of physical recovery in hospitalized patients for …